News & Updates

Show Multimedia Only

Chamomile improves skin recovery in breast cancer patients with radiodermatitis

13 May 2022

A topical formulation containing chitosan-coated Chamomilla recutita (L.) rauschert microparticles does not lower any grade of radiodermatitis (RD) but is effective in reducing grade ≥2 toxicity to improve skin recovery and diminish high-intensity local symptoms in women with breast cancer, a study has shown.

13 May 2022

MRI provides long-term prognosis of patients with biochemical recurrence

13 May 2022

Use of prostatectomy bed magnetic resonance imaging (MRI) can give out long-term prognostic information for assessing patients with biochemical recurrence following prostatectomy, reveals a recent study.

13 May 2022

Smokers at higher risk of death from prostate cancer

13 May 2022

Prostate cancer patients who are also smokers have a greater risk of death, an effect that is further exacerbated by obesity, reports a recent study.

13 May 2022

Neoadjuvant nivolumab plus chemo: New SoC in resectable NSCLC

13 May 2022 by

In patients with resectable non-small-cell lung cancer (NSCLC), neoadjuvant nivolumab in combination with platinum-based chemotherapy significantly improves event-free survival (EFS) and shows a trend towards better overall survival (OS) vs chemotherapy alone, without impeding the feasibility of surgery or increasing adverse events (AEs), according to results of the phase III CheckMate 816 trial.

13 May 2022

Sotorasib continues to impress at 2 years in KRAS G12C–mutant NSCLC

13 May 2022 by

Long-term findings from the pooled phase I/II CodeBreak 100 trial support the efficacy of sotorasib in certain patients with KRAS G12C–mutant non–small cell lung cancer (NSCLC).

13 May 2022

SWOG S1616 suggests PFS benefit with ipi-nivo combo in metastatic/unresectable melanoma

12 May 2022 by

The combination of ipilimumab and nivolumab may provide a progression-free survival (PFS) benefit in patients with metastatic or unresectable melanoma who did not respond to anti-PD-1/anti-PD-L1 therapy, according to a small study presented at AACR 2022.

12 May 2022

Short-term ADT leads to worse survival in prostate cancer patients on IMRT

12 May 2022

Short-term concurrent androgen deprivation therapy (ADT) results in markedly worse overall survival (OS) among intermediate-risk (IR) prostate cancer patients on dose-escalated intensity modulated radiation therapy (IMRT) with daily image-guided RT, reveals a study.

12 May 2022

Apalutamide-related adverse events in prostate cancer common but manageable

12 May 2022

Dermatological adverse events (dAEs) associated with apalutamide, though common, can be managed with topical steroids with or without oral antihistamines, reports a study.

12 May 2022

Allostatic load tied to survival in multiple myeloma

12 May 2022

In patients with multiple myeloma (MM), a higher allostatic load (AL) seems to be an important predictor of worse overall survival (OS), a recent study has found.

12 May 2022

50 Gy recommended dose in concurrent chemoradiotherapy for ESCC

11 May 2022

When considering concurrent chemoradiotherapy (CCRT) in the treatment of patients with esophageal squamous cell carcinoma (ESCC), the 60 Gy dose yields similar survival outcomes but a higher incidence of severe pneumonitis when compared with the lower 50 Gy dose, according to the results of a phase III study.

11 May 2022

News & Updates

Showing Oncology articles

Showing

Specialty:

Chamomile improves skin recovery in breast cancer patients with radiodermatitis

MRI provides long-term prognosis of patients with biochemical recurrence

Smokers at higher risk of death from prostate cancer

Neoadjuvant nivolumab plus chemo: New SoC in resectable NSCLC

Sotorasib continues to impress at 2 years in KRAS G12C–mutant NSCLC

SWOG S1616 suggests PFS benefit with ipi-nivo combo in metastatic/unresectable melanoma

Short-term ADT leads to worse survival in prostate cancer patients on IMRT

Apalutamide-related adverse events in prostate cancer common but manageable

Allostatic load tied to survival in multiple myeloma

50 Gy recommended dose in concurrent chemoradiotherapy for ESCC